Skip to main content

Guideline Updates

NCCN Updates Clinical Practice Guideline for NSCLC

March 03, 2021

On March 3, 2021, The National Comprehensive Cancer Network (NCCN) released an update to its guideline for non-small cell lung cancer (NSCLC).

In the section for first-line therapy for PD-L1 expression-positive NSCLC ≥50% and negative for actionable molecular markers, cemiplimab-rwlc was added as a preferred, category 1, treatment option.

Additionally, in the section for targeted therapy or immunotherapy for advanced or metastatic disease, cemiplimab-rwlc was added as first-line therapy for PDL1 ≥50% NSCLC.—Janelle Bradley

Back to Top